Related Experiment Videos
[Mycoses as opportunistic infections in AIDS patients].
1Instituto di Igiene, Milano, Italien.
Medizinische Klinik (Munich, Germany : 1983)
|December 1, 1991
Summary
Itraconazole effectively treated deep fungal infections like aspergillosis and cryptococcosis in over 100 patients. The antifungal drug demonstrated good tolerance, with successful outcomes in most cases, including invasive pulmonary aspergillosis.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Context:
- Deep fungal infections pose significant health risks, particularly in immunocompromised individuals.
- Itraconazole is a broad-spectrum antifungal agent used for various mycoses.
- This study evaluated itraconazole's efficacy and safety in a large patient cohort in Northern Italy.
Purpose:
- To assess the clinical efficacy of itraconazole in treating deep fungal infections.
- To evaluate the safety and tolerability of itraconazole in a real-world setting.
- To determine the effectiveness of itraconazole for both active infection treatment and relapse prevention.
Summary:
- Over 100 patients with deep fungal infections received itraconazole (200-400 mg/day).
- High response rates were observed in sporotrichosis (1/1), aspergillosis (24/34, including 15/18 cured invasive pulmonary aspergillosis), and cryptococcosis (9/12 treated alone, 8/10 with flucytosine).
- Maintenance therapy in cryptococcosis showed a 42% cure rate with no relapses in 45% of patients.
Impact:
- Itraconazole is a well-tolerated and effective treatment option for various deep fungal infections.
- The findings support itraconazole's role in managing aspergillosis and cryptococcosis, including in human immunodeficiency virus-positive patients.
- Long-term itraconazole use for cryptococcosis prevention demonstrated significant success in preventing relapses.